On 7 January 2015, the National Institute for Health and Care Excellence (NICE) issued a draft clinical practice guideline on the management of type 2 diabetes by the NHS in England and Wales.
23 Jul 2015 Posted in ABPI statement By Commercial
The ABPI agreed overall with many elements of the draft guideline including the need for patient-centred care; the importance of weight loss and dietary management; and recognition of the detrimental impact of hypoglycaemia on patients’ quality of life. However, we shared the concerns of the diabetes community that the section on ‘Blood Glucose Management’ was fundamentally flawed.
On 21 April 2015 NICE acknowledged that it had received extensive responses from registered stakeholders and had made substantial changes to the draft recommendations. On 26 June 2015 NICE opened a second consultation on recommendations for the pharmacological management of blood glucose in adults with type 2 diabetes.
The Association of the British Pharmaceutical Industry (ABPI) would like to thank the guideline development group (GDG) for a second opportunity to respond to the draft NICE Type 2 diabetes guidelines. The overwhelming response from stakeholders, including the ABPI, illustrates how important this guideline is to the complexities of managing people living with type 2 diabetes.
The ABPI acknowledges that there have been many welcome improvements to the draft guideline. However the ABPI still believes that the draft guideline is still missing the opportunity to support an individualised approach to treating diabetes.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811